249P The CDK4/6 inhibitors takeover of the HR+/HER2- locally advanced to metastatic breast cancer market in the EU5: Findings from a real-world study

Palbociclib
DOI: 10.1016/j.annonc.2021.08.532 Publication Date: 2021-09-21T18:45:04Z